You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

SYNALGOS-DC-A Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for SYNALGOS-DC-A?
  • What are the global sales for SYNALGOS-DC-A?
  • What is Average Wholesale Price for SYNALGOS-DC-A?
Summary for SYNALGOS-DC-A
US Patents:0
Applicants:1
NDAs:1
Raw Ingredient (Bulk) Api Vendors: 136
DailyMed Link:SYNALGOS-DC-A at DailyMed
Drug patent expirations by year for SYNALGOS-DC-A

US Patents and Regulatory Information for SYNALGOS-DC-A

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Leitner Pharms SYNALGOS-DC-A acetaminophen; caffeine; dihydrocodeine bitartrate CAPSULE;ORAL 089166-001 May 14, 1986 DISCN No No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

SYNALGOS-DC-A Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory of SYNALGOS-DC

Introduction

SYNALGOS-DC, a combination drug containing aspirin, caffeine, and dihydrocodeine, is used for the relief of moderate to severe pain. Understanding its market dynamics and financial trajectory involves analyzing various factors, including prescription trends, market competition, and regulatory influences.

Prescription Trends

Overall Prescription Volume

The prescription volume of opioid-based medications, including those like SYNALGOS-DC, has been a subject of scrutiny due to concerns over opioid misuse. However, certain trends indicate that while overall opioid prescriptions have been declining in some areas, specific formulations continue to see usage.

For example, the IQVIA report on stimulant trends, although not directly focused on opioids, highlights that prescription patterns can vary significantly by age and gender. While this report does not specifically address SYNALGOS-DC, it suggests that prescription trends can be influenced by demographic factors and changes in medical practice[1].

Demographic Impact

Prescription trends for pain medications like SYNALGOS-DC can be influenced by demographic changes. For instance, the IQVIA report notes that prescriptions for certain medications have increased among specific age groups, such as the 31-40 and 71-80 year olds. This could imply that as the population ages, there may be an increased demand for pain relief medications, potentially affecting the market for SYNALGOS-DC[1].

Market Competition

Consolidation in the Pharmaceutical Industry

The pharmaceutical industry has seen significant consolidation through mergers and acquisitions, which can impact the market dynamics of specific drugs. This consolidation can lead to fewer companies producing and marketing drugs, resulting in greater market domination by certain companies and reduced competition. This trend can affect the pricing and availability of drugs like SYNALGOS-DC[4].

Generic and Brand-Name Competition

SYNALGOS-DC, being a brand-name drug, faces competition from generic versions of similar formulations. The GAO report on brand-name prescription drug pricing notes that generic competition can significantly reduce the market share of brand-name drugs once their patents expire. However, SYNALGOS-DC's unique formulation and brand recognition may help it maintain a market presence despite generic competition[4].

Financial Trajectory

Pricing Dynamics

The pricing of SYNALGOS-DC can be influenced by various factors, including regulatory oversight, market competition, and the overall economic environment. The GAO report highlights that extraordinary price increases are not uncommon in the pharmaceutical industry, especially for brand-name drugs. However, these increases are often subject to scrutiny and may be regulated to ensure affordability and accessibility[4].

Revenue and Expenditure

The financial performance of SYNALGOS-DC is tied to its revenue and expenditure trends. While specific financial data for SYNALGOS-DC is not readily available, the broader trend in drug expenditure suggests that spending on prescription drugs has risen substantially over the past few decades, though this growth is less pronounced when normalized for economic and population growth[3].

Regulatory Influences

Drug Utilization Review (DUR) Boards

Regulatory bodies such as Drug Utilization Review (DUR) Boards play a crucial role in monitoring and managing the use of prescription drugs, including opioids like SYNALGOS-DC. These boards review medication coverage and authorization criteria to ensure safe and effective use. For example, the Oklahoma DUR Board meeting minutes discuss updates on medication coverage and authorization, which can impact the market for specific drugs[5].

Opioid Crisis and Regulatory Response

The opioid crisis has led to increased regulatory scrutiny of opioid-based medications. This has resulted in stricter prescribing guidelines, increased monitoring, and in some cases, reduced availability of these medications. Such regulatory responses can significantly impact the market dynamics and financial trajectory of SYNALGOS-DC.

Market Share and Product Switching

Treatment Categories and Product Switching

The IQVIA report on stimulant trends discusses treatment categories and product switching behaviors, which can be applicable to other prescription drugs. For SYNALGOS-DC, understanding whether patients are starting new therapy or continuing existing treatment can provide insights into market share and potential growth areas[1].

Patient Demographics and Prescribing Practices

Gender and Age Trends

Prescribing practices for SYNALGOS-DC can vary by gender and age. The IQVIA report notes that while males had more stimulant prescriptions dispensed, the gap between males and females narrowed over time. Similar trends might be observed for pain medications, influencing the market dynamics of SYNALGOS-DC[1].

Prescriber Specialties

The specialties of prescribers can also impact the market for SYNALGOS-DC. Psychiatrists and pediatricians are among the top prescribers of certain medications, but nurse practitioners have increasingly become significant prescribers. This shift in prescriber demographics can affect the prescribing patterns and market share of specific drugs[1].

Key Takeaways

  • Prescription Trends: The market for SYNALGOS-DC is influenced by demographic changes and overall trends in prescription drug use.
  • Market Competition: Consolidation in the pharmaceutical industry and competition from generic versions can impact the market share of SYNALGOS-DC.
  • Financial Trajectory: Pricing dynamics, revenue, and expenditure trends are crucial in understanding the financial performance of SYNALGOS-DC.
  • Regulatory Influences: Regulatory bodies and responses to the opioid crisis significantly affect the market dynamics and availability of SYNALGOS-DC.
  • Market Share and Product Switching: Understanding treatment categories and product switching behaviors is essential for analyzing market share and growth potential.

FAQs

Q: How has the opioid crisis impacted the market for SYNALGOS-DC? A: The opioid crisis has led to increased regulatory scrutiny, stricter prescribing guidelines, and reduced availability of opioid-based medications, which can significantly impact the market for SYNALGOS-DC.

Q: What role do DUR Boards play in managing the use of SYNALGOS-DC? A: DUR Boards review medication coverage and authorization criteria to ensure safe and effective use, which can influence the market and prescribing practices for SYNALGOS-DC.

Q: How does consolidation in the pharmaceutical industry affect SYNALGOS-DC? A: Consolidation can lead to greater market domination by fewer companies, potentially reducing competition and affecting the pricing and availability of SYNALGOS-DC.

Q: What is the impact of generic competition on SYNALGOS-DC? A: Generic competition can reduce the market share of brand-name drugs like SYNALGOS-DC once their patents expire, although brand recognition and unique formulations can help maintain market presence.

Q: How do demographic changes influence the market for SYNALGOS-DC? A: Demographic changes, such as an aging population, can increase the demand for pain relief medications, potentially affecting the market dynamics of SYNALGOS-DC.

Sources

  1. IQVIA Report on Stimulant Trends from 2012 - 2021. U.S. Department of Justice, October 31, 2022.
  2. BOARD MEETING AGENDA - Oregon.gov. Oregon.gov, June 6, 2018.
  3. Understanding the Dynamics of Drug Expenditure - IQVIA. IQVIA, 2023.
  4. GAO-10-201, Brand-Name Prescription Drug Pricing. U.S. Government Accountability Office, 2010.
  5. Drug Utilization Review Board - Oklahoma.gov. Oklahoma.gov, October 12, 2022.

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.